Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) PT at $11.64

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received an average rating of “Buy” from the thirteen research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.6364.

A number of brokerages have recently weighed in on TSHA. Truist Financial upgraded Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Needham & Company LLC upped their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Finally, Canaccord Genuity Group upped their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, April 6th.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the transaction, the insider directly owned 1,136,410 shares in the company, valued at $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP grew its stake in Taysha Gene Therapies by 150.0% during the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock worth $75,625,000 after buying an additional 8,250,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Taysha Gene Therapies by 2.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock worth $75,310,000 after acquiring an additional 309,031 shares during the period. Vanguard Group Inc. boosted its position in Taysha Gene Therapies by 3.3% during the 4th quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock worth $72,973,000 after acquiring an additional 418,192 shares during the period. Octagon Capital Advisors LP boosted its position in Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after acquiring an additional 1,892,500 shares during the period. Finally, State Street Corp boosted its position in Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock worth $59,345,000 after acquiring an additional 3,553,619 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $5.40 on Thursday. Taysha Gene Therapies has a twelve month low of $2.25 and a twelve month high of $7.30. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -14.21 and a beta of 1.19. The business has a 50 day simple moving average of $5.72 and a 200-day simple moving average of $5.16.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, equities research analysts expect that Taysha Gene Therapies will post -0.47 earnings per share for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.